PM Girard

Mitochondrial dysfunctions in circulating T lymphocytes from human immunodeficiency virus-1 carriers [see comments]

Antonio Macho, Maria Castedo, Philippe Marchetti et al. · Blood · 1995 · 144 citations · Full text

Life Sciences, Immunology, Molecular Genetics +11

Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial

Chloe Orkin, Jean‐Michel Molina, Eugènia Negredo et al. · The Lancet HIV · 2017 · 96 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Anti-RH immunoglobulin therapy for human immunodeficiency virus-related immune thrombocytopenic purpura

Éric Oksenhendler, P Bierling, Y. Brossard et al. · Blood · 1988 · 86 citations · Full text

Life Sciences, Hematology, Immunology +8

Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial

Laura Ciaffi, Sinata Koulla‐Shiro, Adrien Sawadogo et al. · The Lancet HIV · 2017 · 72 citations

Public Health, Community Health, Pharmacotherapy +17

Quality of life and depression among HIV‐infected patients receiving efavirenz‐ or protease inhibitor‐based therapy in Senegal

M. Poupard, NF Ngom Gueye, Doudou Thiam et al. · HIV Medicine · 2007 · 52 citations · Full text

Medicine, Pharmacology, Psychiatry +16